Cargando…

Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

OBJECTIVE: Clinical trials showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors can improve non-alcoholic fatty liver disease (NAFLD). In this work, a meta-analysis of randomized controlled trials was conducted to evaluate the effect of SGLT2 inhibitors on type 2 diabetes mellitus (T2DM) wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Qiong, Xu, Xinyue, Guo, Li, Li, Jia, Li, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247927/ https://www.ncbi.nlm.nih.gov/pubmed/34220701 http://dx.doi.org/10.3389/fendo.2021.635556

Ejemplares similares

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
por: Jiang, Yu, et al.
Publicado: (2022)

Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
por: Zhou, Bin, et al.
Publicado: (2022)

SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
por: Raj, Henith, et al.
Publicado: (2019)

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
por: Shyangdan, Deepson S, et al.
Publicado: (2016)

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
por: Wong, Chloe, et al.
Publicado: (2021)

Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhu, Yuan, et al.
Publicado: (2021)

Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus – New Findings on SGLT2 Inhibitors
por: Brinkmann, Christian
Publicado: (2021)

Association between dietary glycemic index and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
por: Salavatizadeh, Marieh, et al.
Publicado: (2023)

Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials
por: Wang, Zeyu, et al.
Publicado: (2023)

Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
por: Zhou, Peipei, et al.
Publicado: (2023)

Association of Serum Bilirubin With Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Liang, Chen, et al.
Publicado: (2022)

Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
por: He, Weiwei, et al.
Publicado: (2017)

Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wei, Ran, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Euh, Won, et al.
Publicado: (2021)

Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
por: Qiu, Mei, et al.
Publicado: (2021)

Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
por: Mandal, Amrendra, et al.
Publicado: (2018)

Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials
por: Lee, Kai Wei, et al.
Publicado: (2021)

SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease
por: Mirarchi, Luigi, et al.
Publicado: (2022)

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
por: Ma, Hong, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
por: Wong, Chloe, et al.
Publicado: (2021)

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
por: Liu, Jiali, et al.
Publicado: (2017)

Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)
por: Cuthbertson, Daniel J., et al.
Publicado: (2021)

The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
por: Pokharel, Arbinda, et al.
Publicado: (2021)

Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice
por: David-Silva, Aline, et al.
Publicado: (2020)

SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
por: Dwinata, Michael, et al.
Publicado: (2020)

The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells
por: Wolf, Lisa, et al.
Publicado: (2023)

Comprehensive review of SGLT2 inhibitors’ efficacy through their diuretic mode of action in diabetic patients
por: Lam-Chung, Cesar Ernesto
Publicado: (2023)

Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus
por: Padda, Jaskamal, et al.
Publicado: (2021)

Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study
por: Bañares, Juan, et al.
Publicado: (2022)

The change of non-alcoholic fatty liver disease is associated with risk of incident diabetes
por: Chen, Congling, et al.
Publicado: (2023)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
por: Chen, Xiutian, et al.
Publicado: (2023)

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2018)

SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes
por: Scapaticci, Serena, et al.
Publicado: (2021)

Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes
por: Bayliss, Jacqueline, et al.
Publicado: (2021)

Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis
por: Yang, Liu, et al.
Publicado: (2022)

Integrated analysis of potential gene crosstalk between non-alcoholic fatty liver disease and diabetic nephropathy
por: Yan, Qianqian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_83dlmfjctslt7kauh7af74rogf